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Abstract
Background This cross-sectional and longitudinal study of
breast cancer survivors (BCSs) examines the associations
between arm/shoulder problems (ASPs), which consist of
pain, restricted mobility and lymphedema, and different
aspects of quality of life (QoL).
Methods BCSs who had breast surgery, axillary lymph node
dissection and radiotherapy (n=255) were examined in 2004
(mean 4.1 years post-surgery) and a sub-sample (n=187)
was re-examined in 2007. ASPs was rated clinically in 2004
and by self-report (EORTC BR23) in 2004 and 2007. QoL
was self-reported with The Short Form-36 (SF-36) and The
Impact of Cancer scale (IOC).
Results In 2004 BCSs with ASPs showed significantly
poorer mean scores in most SF-36 domains compared to
those without. No group differences were observed for
positive IOC domains, while BCSs with ASPs showed
significantly poorer mean scores in the negative ones. BCSs
with clinically defined movement restriction showed sig-
nificantly poorer SF-36 and negative IOC mean scores than
those with clinically defined lymphedema. The longitudinal
sub-study of self-rated pain, restricted mobility and lym-
phedema showed significant changes over time only for
negative IOC domains in the pain group. Self-rated
restricted mobility and lymphedema were significantly
associated with most SF-36 domains both in 2004 and
2007, while few were associated with pain. Self-rated pain
and restricted mobility showed significant associations with
negative IOC domains.
Implications for cancer survivors Not only lymphedema,
but pain and restricted mobility in the arm/shoulder are
significantly associated with poor QoL in BCSs at long-
term. These problems should be diagnosed and treated in
order to improve QoL.
Keywords Abduction.Arm morbidity.Breast cancer.
Lymphedema.Pain.Radiotherapy.Quality of life
Introduction
Arm/shoulder problems (ASPs), defined as restricted
shoulder mobility, lymphedema, and/or arm/shoulder pain
are common in breast cancer survivors (BCSs). At the
5 year follow-up the prevalence of arm/shoulder pain is 30–
40%, of lymphedema 10–15%, and of restricted arm/
shoulder mobility is 15–30% among BCSs who had
axillary lymph node dissection [1–5].
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found that although ASPs were among the most common
adverse effects, most studies focused on the relation
between lymphedema and QoL, rather than on restricted
mobility and pain or ASPs in general. One study from 2003
of long-term ASPs following axillary node dissection,
found ASPs to be the most important source of poor QoL
in BCSs [7]. Later studies on physical and mental QoL
have found that ASPs contribute significantly to poor QoL
[1, 8], but most studies concern lymphedema [9, 10].
However, one of these studies demonstrated that BCSs with
other arm problems other than lymphedema had reduction
in scores of mental health that were not observed in BCSs
with lymphedema [1].
Since Bentzen et al. [11] found that 90% of post-
radiotherapy effects in the arm/shoulder tissues occurred
during the first 3.9 years post-treatment, the maximum
effects of ASPs should be seen approximately 4 years after
radiotherapy. Further, in order to catch the full effects on
QoL, use of more than one QoL instrument has been
recommended [12]. Therefore in this study we examined
BCSs treated for stage II–III disease at a mean of 4 and
7 years after diagnosis using both the SF-36 and the
Impact of Cancer scale (IOC). While the SF-36 is a well-
established generic QoL instrument, the IOC is a recently
introduced scale developed by Ganz et al. intended to
specifically “assess a range of problems, issues and
changes that long-term survivors ascribe to their cancer
experience” [13]. The IOC was considered an instrument
with good specific qualities for long-term cancer survivors
according to Pearce et al. [14]. Both QoL instruments were
used to examine associations between ASPs and QoL in
this study.
Our BCSs sample was examined both clinically and
by questionnaire in 2004, and a sub-sample was re-
examined with questionnaire in 2007. Since most QoL
studies of BCSs had focused on lymphedema, we also
wanted to study the associations of restricted arm/
shoulder mobility and arm/shoulder pain as well as
lymphedema with QoL. Restricted mobility and lymphe-
dema were rated by clinical examination in 2004. Arm/
shoulder pain, restricted mobility and lymphedema were
also self-rated in both 2004 and 2007, which gave us an
opportunity for a longitudinal sub-study.
Our study therefore had three aims: 1) To study the
associations between ASPs and QoL domains cross-
sectionally 4 years post-surgery (2004 sample). 2) To
compare associations between restricted shoulder mobil-
ity versus lymphedema and QoL (2004 sample). 3) To
study longitudinal changes in self-rated ASPs scores and
QoL and to compare their associations in 2004 and
2007.
Methods
Patient sampling
BCSs treated for stage II breast cancer between 1998 and
2002 at The Norwegian Radium Hospital (NRH), were
invited to take part in a follow-up survey in 2004/2005. The
survey consisted of a mailed questionnaire and an outpa-
tient clinical examination. The inclusion criterias were: 1)
Curatively intended surgery, followed by loco-regional
radiotherapy; 2) No evidence of relapse since primary
treatment; 3) No other malignant diagnosis; 4) Age
≤75 years at survey.
Among the 415 BCSs fulfilling the inclusion criteria, 23
(6%) declined to participate, and 43 (10%) did not respond,
resulting in 349 BCSs (84%) returning questionnaires in
2004. Among them 318 (91%) also had the outpatient
examination. Fifty-five (17%) BCSs with primary inoper-
able cT3-cT4 tumours, who received neo-adjuvant chemo-
therapy, were excluded in order to obtain a homogenously
treated sample of BCSs. Thus, all included BCSs had pT1-
pT2 tumours and axillary lymph node metastases. However,
eight patients were omitted due to incomplete question-
naires, resulting in a 2004 sample of 255 BCSs. Among
these, 195 women also took part in the 2007 follow-up
survey (2007 longitudinal sample). A flowchart of the study
is shown in Fig. 1.
Treatment modalities
Treatment was based on the guidelines of the Norwegian
Breast Cancer Group (www.nbcg.no). All BCSs had either
415 BCSs
invited in 2004
349 filled
in questionnaires
23 declined
43 did not respond
318 had
clinical examination
31 did not have
clinical examination
263 with operable
breast tumors
55 with inoperable
breast tumors
255 BCSs cross-
sectional 2004 
sample
187 BCSs longitu-
dinal 2004-7 sample 
8 with incomplete
questionnaires
68 did not respond to 
the 2007 invitation or 
had incomplete forms
Fig. 1 Flowchart of the sample of the study
J Cancer Surviv (2011) 5:62–72 63modified radical mastectomy or lumpectomy, and all had
axillary lymph node dissection at level I–II. The target
volume of radiotherapy included the breast after lumpecto-
my, and the chest wall after mastectomy. All BCSs had
adjuvant radiotherapy to the regional lymph nodes, with
50 Gy in 25 fractions. From October 1999, patients who had
removed ≥ 10 axillary nodes without perinodal infiltration
had irradiation only to the axillary apex, as opposed to those
with <10 nodes removed and those having radiotherapy
before that time, who had radiotherapy to the entire
axilla. Post-operative adjuvant chemotherapy with CMF or
FEC and/or tamoxifen was given according to the patient’s
age and the hormone receptor status of the tumour [15].
Measures
Demographic variables
Information on socio-demographic variables was obtained
from the questionnaire and the medical records. Relationship
status was dichotomized as paired (married/cohabiting) and
non-paired (single/separated/divorced/widow) and level of
education into ≤ 12 years or >12 years of basic education.
Employment status was categorized as employed (full or
part-time jobs or students), and not employed.
Cancer-related variables and BMI
Information on the type of breast cancer and its treatment
was obtained from the medical records. Weight and height
was collected at the 2004 survey, and the body mass index
(BMI) was calculated as kg/m
2.
Clinical assessments of shoulder mobility and lymphedema
in 2004
At the clinical examination arm/shoulder mobility was
assessed by two experienced physiotherapists. Goniometer-
based measurements of flexion (forward elevation of the
arm) and abduction (lateral elevation of the arm) were done
on both arms. Based on clinical experience, a reduced range
of motion of ≥ 25° difference between the operated side and
the other was defined as impaired shoulder mobility either
for flexion, abduction or both (n=85).
Lymphedema was assessed by volumetric calculation
using five circumferential measurements on both arms [16].
Lymphedema was defined as either: 1) a difference of ≥
10% in volume between the operated side and the other; or
2) For BCSs with either current use of compression
garment or received treatment for lymphedema and ≥
2 cm increase of any circumference of the operated arm
versus the other arm (n=43).
Self-rating of ASPs in 2004
Self-rating was done by Kwan’s arm problem scale (KAPS)
[8]. The KAPS consists of the Problem subscale rating arm/
shoulder symptoms including pain, swelling, stiffness, use,
and numbness, and the ADL subscale rating impairment in
dressing and other daily activities. All 13 KAPS items were
rated on five point Likert scales from 1 (no symptom or
same as before) to 5 (severe symptom or unable to
perform), and the KAPS score was the sum score of the
items. The KAPS has shown good psychometric properties
in our sample of BCSs [17]. Clinically significant self-rated
ASPs were defined by a KAPS score of ≥ 21.5 [17], and
that was present in 121 BCSs in 2004.
Definition of ASPs present (+) or absent (−) in 2004
We used the findings on the clinical assessment and the
self-rated KAPS scores in 2004 to define two groups
regarding ASPs in both the 2004 and 2007 samples. The
ASPs+ (present) group fulfilled at least two of three criteria:
1) having impaired shoulder mobility; 2) having lymphe-
dema; or 3) KAPS score ≥ 21.5. The ASP- (absent) group
fulfilled one or none of these criteria.
Definition of self-rated ASPs in the longitudinal substudy
(2004–7)
Since BCSs had filled in the EORTC QLQ-BR23 (BR23) a
specific breast cancer module of QoL in both 2004 and
2007 [18], the ASPs questions of the BR23 was used for
the longitudinal study of ASPs in relation to QoL domains
over time. These questions were: During the past week:
“Did you have pain in your arm or shoulder?”; “Did you
have a swollen arm or hand?” and “Was it difficult to raise
your arm or to move it sideways?” The items were rated on
a four point Likert scale with the categories ‘not at all’ =1 ,
‘a little’ =2 ,‘quite a bit’ = 3 and ‘very much’ = 4, which
were used both as continuous measures and dichotomized
as BR23-defined arm/shoulder pain, restricted mobility, and
lymphedema present (quite a bit/very much) or absent (not
at all/a little) [18].
The IOC version 1 (IOCv1)
The IOCv1 is a specific QoL instrument for long-term
cancer survivors [13]. The IOCv1 covers six domains with
10 dimensional subscales, five positive (+) and five
negative (−). The Physical Domain includes Health Aware-
ness (+) and Body Changes (−). The Psychological Domain
concerns Positive Self-evaluation (+) and Negative Self-
evaluation (−). The Spiritual/Existential Domain covers
64 J Cancer Surviv (2011) 5:62–72Positive Life Outlook (+) and Negative Life Outlook (−).
The Social Domain consists of Life Interference (−) and
Values of Relationships (+). Meaning of Cancer (+) and
Health Worries (−) are separate domains (10). All 41 IOC
items are scored by five response categories: 1 (strongly
disagree), 2 (disagree), 3 (neutral), 4 (agree) and 5 (strongly
agree). The mean dimension score is calculated by
summation of the dimensional item scores divided by the
number of items, and mean scores <3 implies disagreement
and >3 means agreement on the domains [13].
Ganz approved the use of the IOCv1 by our group. The
translation of the IOC into Norwegian was made by
professional translators with forward and backward trans-
lations. In the current study the Cronbach’s coefficient
alphas were ≥0.75 for the positive domains and ≥0.85 for
the negative ones.
The SF-36
The SF-36 is a generic QoL measure in common
international use with well-documented psychometric prop-
erties and with normative data of the Norwegian general
population [19]. The items are combined into four physical
domain scales: Physical functioning, Physical role func-
tioning, Bodily pain, General health, summarized as the
Physical Component Summary Scale (PCS); and four
mental domain scales: Vitality, Social functioning, Emo-
tional role functioning and Mental health summarized as
the Mental Component Summary Scale (MCS). The PCS
and MCS are T-transformed so that the Norwegian general
population mean scores were 50 [20].
Statistical analysis
Continuous variables were analyzed with t-tests and
categorical variables with chi-square tests. In case of
skewed distributions, non-parametric tests were applied.
Statistically significant differences in continuous and 2×2
contingency tables were tested for clinical significance
using effect sizes (ESs). For continuous variables we used
Cohen’s coefficient d, and for 2×2 contingency tables we
used differences between arcsine transformed proportions.
ES values ≥ 0.40 were considered as clinically significant
based on the recommendations of Cohen [21–23]. Changes
of the BR-23 defined ASPs scores from 2004 to 2007 were
tested with paired sample t-tests. Correlations were calcu-
lated with Spearman’s coefficient rho. Internal consistencies
of scales and subscales were examined by Cronbach’s
coefficient alpha.
Bivariate and multivariate logistic regression analyses
were used to explore associations between demographic,
cancer-related variables, and the SF-36 and IOCv1 domain
scores as independent variables, and ASPs groups in 2004
and BR-23 defined arm/shoulder pain, restricted mobility,
and lymphedema in 2004 and 2007 as dependent variables.
The strength of the associations was expressed as odds
ratios (OR) with 95% confidence intervals (95%CI). The
analyses were done on SPSS for Windows, version 16.0.
The level of significance was set at p<0.01 due to multiple
comparisons, and all tests were two-sided.
Ethical considerations
The study was approved by the Regional Ethical Committee
of Health Region South of Norway and by the National Data
Inspectorate. All patients gave written informed consent.
Results
Socio-demographic and cancer-related findings (2004
sample)
Of the 255 tumour-free BCSs included, 80 (31%, 95%CI
26–37%) BCSs belonged to the ASP+ group and 175 (69%,
95%CI 63–74%) belonged to the ASP-group.
The following comparisons between the ASP+ and ASP-
groups showed statistical significance: ASP+ had longer
follow-up time, lower proportion of employed BCSs, and
higher proportions with mastectomy and radiotherapy to the
entire axilla (Table 1). The differences in follow-up time
and type of surgery were clinically significant, while extent
of radiotherapy came close (ES=0.39). None of the other
socio-demographic or cancer-related variables showed
significant intergroup differences (Table 1).
ASP groups and QoL (2004 sample)
Compared to the ASP- group, the ASP+ group had
significantly poorer scores in all physical and mental
domains of the SF-36, except for MCS (Table 2). All
statistically significant differences were also clinically
significant.
No significant differences were found between the two
ASP groups on the positive IOC domains. However, all the
negative IOCv1 domains, except Health Worry, showed
significantly higher agreement scores in the ASP+ com-
pared to the ASP- group. All these differences were
clinically significant (Table 2).
We did a multivariate logistic regression analyses with
the significant socio-demographic and cancer–related
variables (Table 1). The SF-36 Bodily pain and Role
emotional and the IOCv1 of Body changes (highest ES for
physical, mental and negative domains, respectively) were
the independent variables and ASP group was the
dependent variable. Only Bodily pain and Body changes
J Cancer Surviv (2011) 5:62–72 65showed significant associations with the ASP+ group (data
not shown)
Clinically rated restricted mobility versus lymphedema
and QoL (2004 sample)
Based on the clinical assessments 85 out of 255 BCSs
(33%) had restricted mobility and 43 (17%) had lymphe-
dema. In bivariate logistic regression analyses all the SF-36
domains except Social functioning, Mental health and
MCS were significantly associated with restricted arm/
shoulder mobility, while none were significantly associated
with lymphedema based on clinical examinations (Table 3).
No significant associations were detected between the
positive IOCv1 domains and reduced mobility or lymphe-
dema. As to negative IOCv1 domains, Life interference was
significantly associated with both reduced mobility and
lymphedema, while Body changes was significantly asso-
ciated only with reduced mobility.
Longitudinal study findings 2004–2007
Of the 255 BCSs participating in 2004, 187 (73%)
delivered valid ratings both in 2004 and 2007. BR23
defined arm/shoulder pain was present in 71 of these BCSs
(38%) in 2004 and 66 (35%) in 2007. Correspondingly, 30
BCSs (16%) had self-rated restricted mobility in 2004 and
29 (16%) in 2007, while lymphedema was reported by 40
(21%) in 2004 and by 42 (22%) in 2007. The correlation
coefficients (rho) for the raw scores were: pain versus
swelling 0.50, pain versus movement 0.64, and swelling
versus movement 0.43 in the 2004 sample. The correlation
between clinically assessed and self-rated BR23 restricted
mobility was 0.46 and for BR23 lymphedema 0.43 in the
2004 sample.
Bivariate logistic regression analyses showed that BR23
restricted arm/shoulder mobility was most often associated
with the SF-36 domains, although BR23 lymphedema
showed nearly as many significant associations both in
2004 and 2007 (Table 4). The BR23 arm/shoulder pain
showed much fewer significant associations with the SF-36
domains, and they all belonged to the 2007 ratings.
Comparisons of the SF-36 domain mean scores in 2004
and 2007 showed no significant differences neither for pain,
mobility nor lymphedema.
Bivariate logistic regression analyses showed that neither
BR23 pain, nor restricted mobility or lymphedema showed
any significant associations with any of the positive IOCv1
Variables in 2004 ASP- ASP+ p ES
a
n=175 n=80
Mean (SD) Mean (SD)
Age at survey 54.5 (8.2) 54.6 (7.7) 0.87
Follow up time-years after surgery 3.9 (0.8) 4.4 (1.4) <0.001 0.50
Body mass index 26.1 (4.4) 27.8 (4.9) 0.01 0.37
N (%) N (%)
Paired civil status 133 (77) 64 (82) 0.35
Low level of education (≤12 years) 99 (58) 51 (64) 0.30
Employed 119 (69) 37 (46) 0.001 0.47
Cancer-related variables
Type of breast cancer surgery <0.001 0.52
Mastectomy 112 (64) 69 (86)
Lumpectomy 63 (36) 11 (14)
Systemic treatment
Received chemotherapy 138 (79) 67 (84) 0.55
Received anti-oesterogen therapy 134 (76) 59 (73) 0.74
Extent of axillary radiotherapy 0.005 0.39
Radiotherapy to axillary apex 121 (69) 40 (50)
Radiotherapy to entire axilla 54 (31) 40 (50)
Tumour size 0.20
pT 1 (≤2 cm) 102 (59) 39 (49)
pT 2 (>2- ≤5 cm) 73 (42) 41 (51)
Lymph node status, mean (SD)
Metastatic lymph nodes 2.9 (2.6) 3.3 (3.4) 0.30
Axillary nodes removed 12.7 (4.3) 12.1 (4.6) 0.30
Table 1 Socio-demographic
and cancer-related characteris-
tics in breast cancer survivors
with (ASP+) and without (ASP-)
arm/shoulder problems (2004
sample)
a Effect size
66 J Cancer Surviv (2011) 5:62–72domains (Table 5). BR23 arm/shoulder pain was signifi-
cantly associated with all negative IOCv1 domains both in
2004 and 2007. BR23 restricted mobility also showed
many significant associations with the negative IOCv1
domains particularly in 2004. In contrast, BR23 lymphe-
dema showed few such associations.
For BCSs reporting BR23 arm/shoulder pain, the IOCv1
domains of Negative outlook, Life interferences and Health
worry showed significant improvement from 2004 to 2007.
No such changes over time were observed for any of the
IOCv1 negative domains in the BR23 reduced mobility or
lymphedema groups (Table 5).
Discussion
In relation to our aims we found: 1) Studied cross-
sectionally, BCSs with clinically defined ASPs (2004)
showed significantly poorer QoL on all SF-36 domains,
except MCS, than BCSs without ASPs. No significant
intergroup differences were observed for the positive
IOCv1 domains, while all the negative IOCv1 domains,
except Health Worry, had significantly higher scores in the
ASP+ group (Table 2). 2) BCSs with clinically assessed
restricted mobility showed significant associations with all
SF-36 domains except MCS and no significant associations
for lymphedema. Neither restricted mobility nor lymphe-
dema showed significant associations with positive IOCv1
domains, but both showed significant associations with the
negative IOCv1 domain of Life interference (Table 3). 3)
The longitudinal study of self-rated ASPs showed that
BR23 restricted mobility and lymphedema were signifi-
cantly associated with most SF-36 domains both in 2004
and 2007, while pain was not (Table 4). Longitudinally
there were no significant changes in the SF-36 domain
scores in any of the three ASPs measures. As for the IOCv1
domain scores, BR23 pain and restricted mobility showed
significant associations with the negative domains, while
lymphedema hardly did so. Only the BR23 pain group
showed significant improvement over time in some of the
negative IOCv1 domains (Table 5).
Our results where BCSs with other self-reported arm
symptoms than lymphedema had significantly poorer QoL
in more domains of IOCv1, complement the findings of
Ahmed et al. reporting similar findings using SF-36 [1]. We
were also in agreement with Ahmed et al. [1] who reported
that self-reported ASPs were associated with low QoL
8 years after diagnosis. Among the SF-36 domains with the
Quality of life domains 2004 ASP- ASP+ p ES
a
n=175 n=80
Mean (SD) Mean (SD)
SF-36
Physical functioning 82.2 (15.9) 67.6 (20.3) <0.001 0.84
Role physical 65.7 (39.8) 37.3 (41.6) <0.001 0.70
Bodily pain 71.0 (26.1) 49.1 (25.0) <0.001 0.85
General health 74.9 (20.6) 60.8 (23.9) <0.001 0.65
Vitality 58.2 (21.7) 44.9 (20.0) <0.001 0.63
Social functioning 87.8 (20.5) 75.8 (24.1) <0.001 0.55
Role emotional 86.0 (29.7) 65.2 (42.4) <0.001 0.61
Mental health 80.5 (14.0) 73.9 (17.4) 0.007 0.44
PCS 46.7 (9.9) 38.2 (10.4) <0.001 0.85
MCS 53.0 (8.3) 50.1 (11.1) 0.13 –
Positive IOC dimensions
Health awareness 4.0 (0.7) 4.0 (0.6) 0.48 –
Positive self-evaluation 3.6 (0.6) 3.6 (0.6) 0.80 –
Positive outlook 3.7 (0.8) 3.7 (0.8) 0.65 –
Values of relationship 3.5 (0.9) 3.5 (0.9) 0.12 –
Meaning of cancer 3.3 (0.7) 3.4 (0.8) 0.20 –
Negative IOC dimensions
Body changes 2.6 (1.0) 3.6 (0.9) <0.001 1.03
Negative self-evaluation 1.9 (0.8) 2.3 (0.9) 0.007 0.46
Negative outlook 2.7 (0.9) 3.1 (1.0) 0.005 0.43
Life interference 2.9 (0.8) 3.5 (0.7) <0.001 0.78
Health worry 3.5 (0.9) 3.6 (1.0) 0.23 –
Table 2 Quality of life domain
scores in breast cancer survivors
with (ASP+) and without (ASP-)
arm/shoulder problems (2004
sample)
aEffect size
J Cancer Surviv (2011) 5:62–72 67lowest scores in 2004 were Role physical and Vitality and
PCS all of which were significantly associated with restricted
mobility. This indicates that BCSs with such impairment,
more than with lymphedema, have problems in daily
activities and poorer emotional well-being. This is also
confirmed by the stronger associations with Body changes
and Life interferences observed on the IOCv1 scale.
Generally, the mean QoL scores did not change
significantly from 2004 to 2007. This finding indicates that
the QoL of BCSs seems firmly established at a mean of
4 years since diagnosis. The exception is the score
reduction in three negative IOCv1 domains in BCSs with
self-rated arm/shoulder pain, which may be due to response
shift of the patients’ ability to adapt to their limitations over
time [24]. Our findings are in contrast to those of Engel et
al. who found a reduction of self-reported arm problems
from year 1 to 5 after diagnosis, which indicated that QoL
changes were more common in the first years after
diagnosis [7].
Our findings of strong associations between restricted
mobility and several QoL domains as opposed to
findings in lymphedema, complement findings of
Thomas-Maclean et al. [25] reporting disability related
to shoulder dysfunctions. Studies of lymphedema have
mainly compared QoL in BCSs with and without
lymphedema or with normative data [10]. An interesting
finding in this regard is the weak associations between
clinically rated lymphedema and the SF-36 domains, but
the strong associations with self-rated lymphedema.
Perhaps the moderate correlation of 0.43 (18.5% explained
variance) between the two measures of lymphedema could
explain this divergence. Another explanation could be that
self-rating of both lymphedema and QoL leads to higher
concordance than when lymphedema is rated clinically by
physiotherapists. Smoot et al. [26], in a study of BCSs
found low correlations between objective and self-reported
measures of physical impairments such as range of
movement and functional acti v i t i e s .T h es a m eo b s e r v a -
tions are reported in other studies, with higher incidence
and severity of arm/shoulder symptoms in self-reported
ASPs compared to clinical evaluation [27].
It is well known that pain has a strong influence on both
physical and mental QoL in BCSs [4]. Lauridsen et al.
reported that BCSs with impaired shoulder mobility had
significantly higher frequency of pain in shoulder, arm or
neck compared to BCSs with normal shoulder function
Quality of life domains 2004 Restricted mobility Lymphedema
+ n=85 /−n=170 + n=43 /−n=212
OR (95%CI) p OR (95%CI) p
SF-36
Physical functioning 0.96 (0.95–0.98) <0.001 0.98 (0.96–0.99) 0.01
Role physical 0.99 (0.98–0.99) <0.001 1.00 (0.99–1.00) 0.34
Bodily pain 0.99 (0.98–0.99) <0.001 0.99 (0.98–1.00) 0.13
General health 0.99 (0.98–0.99) <0.001 0.99 (0.98–1.00) 0.13
Vitality 0.98 (0.97–0.99) 0.002 1.00 (0.98–1.01) 0.55
Social functioning 0.99 (0.98–1.00) 0.04 0.99 (0.98–1.01) 0.44
Role emotional 0.99 (0.98–0.99) <0.001 1.00 (0.99–1.01) 0.37
Mental health 0.99 (0.97–1.00) 0.10 1.00 (0.98–1.02) 0.67
PCS 0.94 (0.92–0.97) <0.001 0.98 (0.94–1.00) 0.06
MCS 0.98 (0.98–1.01) 0.26 1.00 (0.97–1.04) 0.90
Positive IOC dimensions
Health awareness 0.87 (0.61–1.21) 0.46 0.94 (0.60–1.49) 0.80
Positive self-evaluation 0.88 (0.58–1.34) 0.54 0.89 (0.53–1.51) 0.67
Positive outlook 1.06 (0.75–1.49) 0.75 1.13 (0.73–1.75) 0.58
Values of relationship 1.10 (0.82–1.53) 0.53 1.48 (0.97–2.24) 0.07
Meaning of cancer 1.26 (0.89–1.79) 0.19 1.17 (0.76–1.82) 0.47
Negative IOC dimensions
Body changes 1.92 (1.46–2.53) <0.001 1.50 (1.09–2.07) 0.01
Negative self-evaluation 1.34 (0.99–1.83) 0.06 1.43 (0.98–2.09) 0.06
Negative outlook 1.32 (1.00–1.73) 0.05 1.30 (0.92–1.83) 0.13
Life interference 1.82 (1.29–2.56) 0.001 2.08 (1.34–3.23) 0.001
Health worry 1.04 (0.78–1.38) 0.80 1.05 (0.73–1.49) 0.81
Table 3 Bivariate logistic
regression analyses of quality of
life domain scores in breast
cancer survivors with reduced
arm/shoulder mobility and
lymphedema as dependent
variables (2004 sample)
68 J Cancer Surviv (2011) 5:62–72[28]. Although not an aim in our study, we confirmed these
results on the self-rated data both in 2004 and 2007, but we
also found such differences at both time points in BCSs
with self-rated lymphedema.
A recent review, studying the consequences of axillary
dissection and radiotherapy, showed more shoulder
morbidity after these treatment modalities than in patients
who did not receive them [29]. This conclusion was
supported by both Peuckman et al. [4] and Hopwood et al.
[30] who reported associations between radiotherapy and
arm/shoulder pain. BCSs with the longest follow-up time
had more frequently mastectomy and radiotherapy to the
entire axilla. This may explain the association between
increasing follow-up time and presence of ASPs observed
in 2004. However, in our study there were few significant
differences in the mean QoL domain scores from 4 to
7 years post-surgery, indicating established stability of
QoL.
New treatment modalities for breast cancer have been
introduced during the last decade, and the incidence of
ASPs is decreasing [31]. Significantly lower proportions of
severe lymphedema were found after breast conserving
surgery compared to radical modified mastectomy [32, 33].
Further, the ALMANAC trial reported less lymphedema,
but no significant difference in impaired shoulder mobility,
12 months after sentinel node biopsy compared to axillary
dissection [34]. Other studies have reported similar results
[35].
After surgery about 90% of BCSs in our 2004 sample
had received information about lymphedema including
clinical manifestations and treatment opportunities. Ahmed
et al. [1] found that the information about lymphedema was
insufficient, but lymphedema still received treatment
priority compared to other arm/shoulder problems. Inter-
estingly, in that study BCSs with other arm/shoulder
problems showed more mental distress than BCSs with
lymphedema.
However, we did not find significant associations of
BCSs with clinically reduced mobility and lymphedema
and SF-36 Mental health, but on self-rating such an
association was observed in 2004 but not in 2007.
Our results have to be considered in the light of some
limitations. One is that the Norwegian health care system
gives treatment close to free of charge to all citizens, and
this fact may limit the generalizability of our findings to
samples from countries with different organization of their
Table 4 Mean scores and bivariate associations of SF-36 domains and self-reported arm/shoulder pain, restricted mobility and lymphedema in
2004 and 2007
Short Form 36
Domains
Arm/shoulder pain
a Restricted arm/shoulder mobility
b Lymphedema
c
OR p mean (SD) p OR p mean (SD) p OR p mean (SD) p
Physical functioning
04
0.97 0.27 66.3 (19.9) 0.08 0.96 <0.001 61.5 (19.8) 0.47 0.96 <0.001 62.9 (20.2) 0.24
Physical functioning
07
0.98 0.21 69.5 (20.6) 0.96 <0.001 63.7 (21.8) 0.97 <0.001 65.8 (22.2)
Role physical 04 0.99 0.33 35.5 (38.4) 0.17 0.98 0.001 30.0 (35.6) 0.67 0.98 <0.001 31.6 (39.3) 0.81
Role physical 07 0.98 0.03 40.9 (42.4) 0.98 <0.001 32.5 (42.6) 0.99 <0.001 32.9 (42.0)
Bodily pain 04 0.95 0.01 43.8 (20.8) 0.06 0.96 <0.001 40.8 (20.7) 0.39 0.97 <0.001 46.2 (22.2) 0.62
Bodily pain 07 0.96 0.01 48.1 (21.9) 0.96 <0.001 44.0 (22.6) 0.97 <0.001 47.7 (21.8)
General health 04 0.98 0.25 57.1 (23.6) 0.80 0.97 <0.001 54.4 (22.5) 0.73 0.96 <0.001 53.7 (25.1) 0.47
General health 07 0.97 <0.001 57.7 (26.2) 0.97 <0.001 52.9 (30.2) 0.97 <0.001 51.4 (28.6)
Vitality 04 0.96 0.09 43.9 (19.1) 0.47 0.97 0.003 42.5 (19.0) 0.87 0.97 <0.001 41.5 (16.2) 0.56
Vitality 07 0.96 <0.001 45.7 (20.4) 0.97 0.005 41.8 (22.4) 0.98 0.03 43.0 (21.6)
Social functioning 04 0.95 0.06 75.7 (23.5) 0.66 0.97 0.001 70.8 (25.7) 0.85 0.98 0.004 74.0 (23.3) 0.68
Social functioning 07 0.98 0.001 77.0 (24.9) 0.97 0.001 70.0 (24.9) 0.99 0.009 75.7 (26.3)
Role emotional 04 0.98 0.13 69.3 (41.2) 0.54 0.98 <0.001 54.4 (45.9) 0.42 0.99 0.004 65.4 (42.9) 0.95
Role emotional 07 0.99 0.001 65.7 (43.9) 0.99 0.02 62.2 (46.1) 0.99 0.001 64.9 (43.8)
Mental health 04 0.95 0.13 73.1 (16.5) 0.40 0.96 <0.001 69.2 (18.4) 0.04 0.97 0.005 72.4 (17.4) 0.62
Mental health 07 0.97 0.006 74.6 (17.2) 0.98 0.05 73.6 (17.8) 0.97 0.02 73.5 (18.2)
PCS 04 0.95 0.20 36.4 (9.7) 0.03 0.93 <0.001 35.6 (8.5) 0.95 0.92 <0.001 35.6 (9.7) 0.67
PCS 07 0.91 <0.001 38.3 (10.5) 0.92 <0.001 35.5 (11.1) 0.94 <0.001 36.1 (10.9)
MCS 04 0.92 0.11 51.0 (10.5) 0.71 0.95 0.007 48.3 (11.5) 0.34 0.97 0.12 50.5 (10.4) 0.80
MCS 07 0.97 0.10 50.6 (10.1) 0.98 0.31 50.0 (9.3) 0.97 0.10 50.9 (10.1)
aPain in 2004 n=71 and in 2007 n=66
bRestricted mobility in 2004 n=30 and in 2007 n=29
cLymphedema in 2004=40 and in 2007 n=42
J Cancer Surviv (2011) 5:62–72 69health care systems. Our design could be criticized for not
having more focus on clinical examination of arm/shoulder
pain which only was rated by two of 13 items of the KAPS.
Our findings concerning pain in 2004 should be considered
in this perspective. Some of our study groups had small
sample sizes, which imply considerable risk of type II
statistical errors, and non-significant findings in small
groups could be significant in bigger samples. With the
smallest groups of n=29/30 (restricted self-rated mobility
in 2004 and 2007), only the big group differences with
effect sizes of Cohen’s coefficient d >0.90 would be
significant. However, many of our other subgroup had
sample sizes in which moderate effects sizes would show
significance.
Some strengths of our study also should be mentioned.
The classification of impaired abduction and lymphedema
were based on objective assessment, thereby reducing the
risk of misclassification. Including the 2007 follow-up, data
enabled us to study eventual changes in the associations
between ASPs and QoL over a longer time span. By setting
the p at <0.01 we also reduced the risk for spurious positive
associations in our analyses.
Our study has an important clinical message concerning
BCSs, namely that attention to ASPsother than lymphedemais
important, in particular restricted mobility. The efficacy of
physiotherapyuponarm/shoulderfunctionandpainhas mainly
been studied during the first months after primary surgery [36].
To our knowledge no studies have been published showing
results of interventions for shoulder mobility on a long term
basis. We therefore see the need for more clinical trials,
studying different interventions aimed at preventing long-term
ASPs or achieving improvement of ASPs.
In conclusion, ASPs in BCSs seem to have a consider-
able and long-lasting effect on physical QoL and negative
aspects of the IOC measurements. Only self-rated lymphe-
dema show significant associations with QoL in our study.
However, reduced arm/shoulder mobility had a strong and
lasting influence on QoL. More clinical attention should
therefore be given to other aspects of ASPs in addition to
lymphedema.
Table 5 Mean scores and bivariate associations of IOCv1 domains and self-reported arm/shoulder pain, restricted mobility and lymphedema in
2004 and 2007
Impact of cancer scale
version1 domains
Arm/shoulder pain
a Restricted arm/shoulder mobility
b Lymphedema
c
OR p mean
(SD)
p OR p mean
(SD)
p OR p mean
(SD)
p
Health awareness 04 1.11 0.64 4.0 (0.7) 0.06 1.37 0.31 4.1 (0.7) 0.93 0.46 0.20 4.0 (0.6) 0.64
Health awareness 07 0.06 0.46 3.9 (0.7) 1.15 0.66 4.1 (0.6) 0.44 0.22 4.0 (0.6)
Positive self-evaluation
04
1.07 0.78 3.6 (0.6) 0.03 1.50 0.23 3.8 (0.6) 0.001 0.76 0.68 3.7 (0.4) 0.006
Positive self-evaluation
07
0.15 0.05 3.6 (0.6) 1.64 0.14 3.5 (0.7) 0.85 0.76 3.5 (0.5)
Positive outlook 04 1.06 0.76 3.8 (0.8) 0.22 1.26 0.38 3.9 (0.6) 1.00 1.06 0.79 3.9 (0.7) 0.04
Positive outlook 07 0.11 0.16 3.7 (0.7) 1.14 0.64 3.9 (0.7) 0.58 0.36 3.7 (0.7)
Values of relationship 04 1.45 0.04 3.5 (0.9) 0.03 1.41 0.17 3.7 (0.7) 0.01 0.86 0.47 3.8 (0.7) 0.04
Values of relationship 07 0.06 0.47 3.4 (0.9) 1.11 0.67 3.4 (0.8) 0.85 0.73 3.6 (0.6)
Meaning of cancer 04 1.28 0.21 3.3 (0.8) 0.07 1.75 0.04 3.6 (0.8) 0.47 1.37 0.50 3.6 (0.7) 0.38
Meaning of cancer 07 0.01 0.86 3.2 (0.8) 1.30 0.30 3.5 (1.0) 0.92 0.86 3.4 (0.9)
Body changes 04 2.57 <0.001 2.9 (1.1) 0.27 2.34 <0.001 3.7 (1.2) 0.19 5.82 0.009 3.7 (0.9) 0.04
Body changes 07 2.15 <0.001 3.0 (1.1) 1.90 0.002 3.9 (1.0) 1.63 0.005 3.6 (1.1)
Negative self-evaluation
04
2.09 <0.001 2.0 (0.9) 0.58 2.02 0.002 2.5 (1.0) 0.94 3.24 0.03 2.6 (0.9) 0.25
Negative self-evaluation
07
2.10 <0.001 2.0 (0.9) 1.69 0.02 2.5 (1.1) 1.59 0.02 2.5 (1.0)
Negative outlook 04 1.84 <0.001 2.8 (1.0) 0.002 2.00 0.002 3.3 (1.2) 0.47 1.25 0.50 3.3 (0.9) 0.18
Negative outlook 07 1.77 <0.001 2.6 (1.0) 1.64 0.02 3.2 (1.2) 1.33 0.10 3.2 (1.0)
Life interferences 04 3.30 <0.001 3.1 (0.8) <0.001 3.13 <0.001 3.7 (0.7) 0.54 2.26 0.14 3.8 (0.7) 0.55
Life interferences 07 2.36 <0.001 2.8 (1.2) 1.88 0.001 3.2 (1.3) 1.68 0.001 3.7 (1.2)
Health worry 04 1.67 0.007 3.5 (0.9) 0.001 2.14 0.004 4.0 (1.1) 0.49 2.07 0.09 4.0 (0.8) 0.11
Health worry 07 1.64 0.003 3.4 (1.0) 1.58 0.04 3.9 (1.0) 1.28 0.17 3.8 (0.9)
aPain in 2004 n=71 and in 2007 n=66
bReduced mobility in 2004 n=30 and in 2007 n=29
cLymphedema in 2004 n=40 and in 2007 n=42
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